Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Fortress Biotech Inc (FBIO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 201,109
  • Shares Outstanding, K 50,530
  • Annual Sales, $ 16,480 K
  • Annual Income, $ -55,100 K
  • 36-Month Beta 1.17
  • Price/Sales 13.15
  • Price/Cash Flow 0.00
  • Price/Book 1.43

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.95 +0.76%
on 10/20/17
4.91 -18.94%
on 10/11/17
-0.53 (-11.75%)
since 09/20/17
3-Month
3.78 +5.29%
on 08/11/17
5.13 -22.42%
on 08/30/17
-0.69 (-14.78%)
since 07/20/17
52-Week
1.88 +111.70%
on 12/19/16
5.13 -22.42%
on 08/30/17
+1.39 (+53.67%)
since 10/20/16

Most Recent Stories

More News
Mustang Bio Announces $12.8 Million Grant to Fund Phase 1 Trial of CAR T Therapy MB-101 in Malignant Glioma

Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a Fortress Biotech, Inc. (NASDAQ:FBIO) company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered...

FBIO : 3.98 (-7.23%)
MBIO : 8.90 (-4.30%)
Checkpoint Therapeutics Initiates Phase 1 Study of Anti-PD-L1 Antibody CK-301

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the first patient has been dosed in a Phase 1 clinical study evaluating the safety...

FBIO : 3.98 (-7.23%)
CKPT : 6.25 (-6.02%)
Avenue Therapeutics Announces Dosing of First Patient in Pivotal Phase 3 Clinical Trial of Intravenous Tramadol for the Management of Postoperative Pain

Avenue Therapeutics, Inc. (NASDAQ:ATXI) ("Avenue"), a Fortress Biotech (NASDAQ:FBIO) Company, today announced that the first patient has been dosed in the pivotal Phase 3 clinical trial of intravenous...

FBIO : 3.98 (-7.23%)
ATXI : 4.55 (-5.21%)
Checkpoint Therapeutics to Present at the Ladenburg Thalmann 2017 Healthcare Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present...

FBIO : 3.98 (-7.23%)
CKPT : 6.25 (-6.02%)
Mustang Bio Announces Expansion of CAR T Pipeline into CD20-Directed Immunotherapies

Entered license agreement with Fred Hutchinson Cancer Research Center for CD20-directed CAR T

FBIO : 3.98 (-7.23%)
MBIO : 8.90 (-4.30%)
Checkpoint Therapeutics Receives Orphan Drug Designation for CK-101 for the Treatment of EGFR Mutation-Positive Non-Small Cell Lung Cancer

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation...

FBIO : 3.98 (-7.23%)
CKPT : 6.25 (-6.02%)
Checkpoint Therapeutics to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ:CKPT), a Fortress Biotech (NASDAQ:FBIO) company, today announced that James F. Oliviero, President and Chief Executive Officer of Checkpoint, will present...

FBIO : 3.98 (-7.23%)
CKPT : 6.25 (-6.02%)
Fortress Biotech to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

Fortress Biotech, Inc. (NASDAQ:FBIO) ("Fortress"), a biopharmaceutical company dedicated to acquiring, developing and commercializing novel pharmaceutical and biotechnology products, today announced that...

FBIO : 3.98 (-7.23%)
Mustang Bio to Present at the CAR-TCR Summit 2017

Mustang Bio, Inc. ("Mustang") (NASDAQ:MBIO), a Fortress Biotech (NASDAQ:FBIO) Company focused on the development of novel immunotherapies based on proprietary chimeric antigen receptor engineered T cell...

FBIO : 3.98 (-7.23%)
MBIO : 8.90 (-4.30%)
Fortress Biotech Forms New Subsidiary, Aevitas Therapeutics, Inc., to Develop Novel AAV Gene Therapy Treatments for Complement-Mediated Diseases

Fortress Biotech, Inc. (Nasdaq:FBIO) today announced the formation of a new subsidiary company, Aevitas Therapeutics, Inc. ("Aevitas"), to develop novel gene therapy approaches for complement-mediated...

FBIO : 3.98 (-7.23%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 72% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators mostly agree with the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States.

See More

Support & Resistance

2nd Resistance Point 4.51
1st Resistance Point 4.24
Last Price 3.98
1st Support Level 3.83
2nd Support Level 3.69

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart